References
- Kernéis S, Valade S, Geri G, et al. Cefoxitin as a carbapenem-sparing antibiotic for infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Dis (Lond). 2015;47:789–795.
- Rodríguez-Baño J, Navarro MD, Retamar P, et al. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167–174.
- Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus piperacillin–tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015;36:981–985.
- Karaman S, Vural S, Yildirmak Y, et al. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia. Pediatr Blood Cancer. 2012;58:579–583.
- Tamma PD, Rodriguez-Baňo J. The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections. Clin Infect Dis. 2017;64:972–980.
- Ghafur A, Tayade A, Kannaian PD. Clinical profile of patients treated with cefepime/tazobactam: a new sz-lactam/sz-lactamase inhibitor combination. Jmid. 2012;2:79–86.
- Fugate JE, Kalimullah EA, Hocker SE, et al. Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy. Crit Care. 2013;17:R264.
- Garces EO, de Azambuja MFA, da Silva D, et al. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol. 2008;17:526–534.